AbbVie Agrees to Acquire Nimble Therapeutics
This will bring Nimble’s psoriasis and inflammatory bowel disease treatment under AbbVie’s pipeline.
Stock.adobe.com
AbbVie will acquire Nimble Therapeutics, according to a newly announced agreement. As a result, Nimble’s peptide synthesis, screening, and optimization platform will be added the AbbVie’s portfolio, improving the company’s ability to discover and optimize oral peptide therapeutics. Alongside that, AbbVie will also add Nimble’s investigational oral peptide IL23R inhibitor, which is in preclinical development, to its pipeline. This drug is being developed as a treatment for psoriasis and inflammatory bowel disease.
According to the terms of the agreement, AbbVie will make a cash payment of $200 million to acquire Nimble. The two companies have not announced when the deal is expected to close.
In a press release, AbbVie’s senior vice president and global head of discovery research Jonathon Sedgwick, PhD, said, “The addition of Nimble's pipeline to AbbVie's existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity. Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases."
Nimble Therapeutics founder and chief executive officer Jigar Patel, PhD, added, “Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, Nimble's novel oral therapies will be well-positioned to reach more people living with autoimmune diseases. The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline."
Earlier this month, AbbVie announced that it had completed another acquisition, this time for Aliada Therapeutics.2 The two companies first announced their agreement back late October of this year, at which point AbbVie stated that it would acquire all of Aliada’s outstanding equity for $1.4 billion in cash.3
In a press release issued at the time of the deal’s completion, AbbVie vice president of neuroscience development Dawn Carlson, MD, MPH, said, “Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age. With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform."
This deal brings ALIA-1758 under AbbVie’s pipeline. The drug, an anti-pyroglutamate amyloid beta antibody, is being developed for the treatment of Alzheimer’s disease and is in Phase I clinical trials.
Sources
- AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline. AbbVie. December 13, 2024. https://news.abbvie.com/2024-12-13-AbbVie-to-Acquire-Nimble-Therapeutics,-Further-Strengthening-Immunology-Pipeline
- AbbVie Completes Acquisition of Aliada Therapeutics. AbbVie. December 11, 2024. Accessed December 16, 2024. https://news.abbvie.com/2024-12-11-AbbVie-Completes-Acquisition-of-Aliada-Therapeutics
- AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline. AbbVie. October 28, 2024. Accessed December 16, 2024. https://news.abbvie.com/2024-10-28-AbbVie-to-Acquire-Aliada-Therapeutics,-Strengthening-Focus-in-Alzheimers-Disease-and-Neuroscience-Pipeline
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
